1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62:10–29.
2. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol. 2011;59:51–60.
3. Castellucci P, Picchio M. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2377-z
4. Dost RJ, Glaudemans AWJM, Breeuwsma AJ, de Jong IJ. Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2398-7
5. Schwarzenböck SM, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer. Eur J Nucl Med Mol Imaging. 2013. doi: 10.1007/s00259-013-2404-0